Do Wall Street Analysts Like Eli Lilly Stock?

Headquartered in Indianapolis, Eli Lilly and Company (LLY) is a leading pharmaceutical company that offers a diversified product range, including new successful drugs, and maintains a robust pipeline. With an impressive market cap of $774.6 billion, Eli Lilly has expanded its portfolio through acquisitions like ImClone Systems (Erbitux), ICOS Corporation (Cialis), Hypnion, CoLucid Pharmaceuticals (Reyvow), Loxo Oncology, and Dermira.

Shares of the drug maker have outshined the broader market over the past year. While LLY has surged 92.6% over this time frame, the broader S&P 500 Index ($SPX) is up 24.5%. In 2024, the stock has returned 40.7%, while SPX rallied 9.8% on a YTD basis.